Story thread · 4 reports / 3 sources
Pharvaris' stock jumps on pivotal success in rare genetic disease
endpts.com · 6d
How the coverage leans
Across 3 sources · syndicated copies counted once
Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease. The experimental drug, an extended-release version of deucrictibant, is designed to prevent swelling attacks in patients with a rare disease ...
First report: Pharvaris rises on late-stage trial win for hereditary angioedema drug — seekingalpha.com, 6d
The coverage
- Pharvaris' Genetic Disorder Drug Meets Main Goal in Late-stage Trial
medscape.com · 6d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.